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Treatment of human myeloid leukemic ells with phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) is associated with activation 
and then partial down-regulation of protein kinase C activity. Previous work has suggested that the activation of protein kinase C by TPA 
contributes to the decrease in c-tnyc expression during differentiation of these cells. The present studies demonstrate that the decline in c-myc mRNA 
levels following exposure of HL-60 cells to TPA is preceded by an increase in expression of this gene. In contrast, exposure of HL-60 ceils to 
inhibitors of protein kinasc C activity is associated with down-modulation of c-myc expression. Similar findings have been obtained in U-937 
myeloid leukemia cells. Taken together, these findings suggest that phorbol esters have a biphasic effect on c-tnyc expression. Whereas the activation 
of protein kinasc C by phorbol esters may be associated with an increase in c-myr gene expression, the subsequent partial down-regulation of kinase 
activity may initiate a cascade of events resulting in the down-modulation of c-myc expression. 
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1. INTRODUCTION 
Phorbol esters induce the terminal differentiation of 
several human myeloid leukemia cell lines [ 11. The iden- 
tification of protein kinase C as the phorbol ester re- 
ceptor has indicated that the pleiotropic effects of TPA 
are related to the activation of this enzyme [2]. Trans- 
location of protein kinase C to the cell membrane is 
followed by proteolytic degradation of the enzyme, pre- 
sumably through the activity of a calcium-activated 
neutral protease [3]. This degradation is associated with 
a decrease in enzyme activity [4], a decrease in protein 
level as assessed by immunoblotting [4], and a decrease 
in the number of phorbol ester binding sites [5]. In this 
regard, binding of [20-3H]phorbol 12,13_dibutyrate 
([3H]PDB) to HL-60 cells reaches maximal evels at 15- 
20 min and then decreases by 60-70% at 1 h [5]. A 
variant HL-60 subclone which exhibits no down-regula- 
tion of [“HIPDB binding was, unlike the parent HL-60 
cell line, refractory to differentiation induction by phor- 
bol esters [5]. These findings suggest that the down- 
regulation of protein kinase C by phorbol esters may be 
an important event in cellular differentiation. 
TPA induces both HL-60 and U-937 cells to differen- 
tiate along the monocytic lineage [6,7]. This differentia- 
tion is associated with a decrease in c-myc expression 
[6,7]. Previous studies have indicated that a decrease in 
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c-myc mRNA levels is necessary and perhaps sufficient 
for induction of hematopoietic ell differentiation [8,9]. 
Since activation of protein kinase C is associated with 
induction of c-myc expression in certain resting cells 
[lo], we undertook studies to investigate the hypothesis 
that the dual effects of phorbol esters on protein kinase 
C activity may correlate with differential expression of 
the c-myc gene in myeloid leukemia cells. The results 
demonstrate that translocation of protein kinase C by 
phorbol ester is initially associated with an increase in 
c-myc transcripts and that down-regulation of protein 
kinase C is associated with a decrease in expression of 
this gene. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
HL-60 and U-937 cells (American Type Culture Collection, Rock- 
ville, MD) were grown as described [I I]. TPA was obtained from 
Sigma Chemical Co., St. Louis, MO. I-(5-isoquinolinylsulfonyl)-2- 
Methylpiperazine (H-7) and N-(2-guanidinoethyl)-5-isoquinolinsulfo- 
namide (HA1004) (Seikagaku America, Inc.) were dissolved in phos- 
phate-buffered saline (PBS). Staurosporine (Sigma) was dissolved in 
dimethylsulfoxide (DMSO). The final concentration of DMSO in all 
experiments was 0. I %. Sangivamycin (provided by the Natural Pro- 
ducts Branch, National Cancer Institute) was used at a final concen- 
tration of IO PM. 
2.2. Northern-blot analysis 
Total cellular RNA was isolated by the guanidine isothiocyanate/ 
cesium chloride method, separated in a 1% agarose/2.2 M formalde- 
hyde gel, transferred to a nitrocellulose filter and hybridized to the 
following 32P-labeled DNA probes: (1) the 1.8-kb ClaIIEcoRI frag- 
ment containing the human c-myc 3’ exon purified from the pM (X1-3 
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Fig. I, Effects of TPA on c-myc expression in HL-60 cells. HL-60 cells 
were treated with 32 nM TPA. Total cellular RNA (20 ,&lane) was 
isolated at the indicated times for Northern analysis with the “P- 
labeled c-,qc probe. 
RC plasmid [l2]; and (2) the 2.0-kb Ps!I cDNA of the chicken p-actin 
gene purified from the pAl plasmid [13]. 
HL-60 cells (2~10~) were suspended in 0.4 ml ice-cold TEM buffer 
(20,~M Tris-HCI, pH 7.5.0.5 mM EDTA, 0.5 mM EGTA, and IO mM 
/?-mercdptoethanol) containing 25,ugiml leupeptin and 25,ugiml apro- 
tinin. The cells were disrupted using a syringe and 2S-gauge needle, 
incubated on ice for 30 min and then spun in a microccntrifuge for IO 
min. The supernatant (cytosol) was kept for partial purification on 
DEAE cellulose columns, The pellet (membrane fraction) was suspen- 
ded in 0.4 ml ice-cold TEM buffer containing 0.5% Triton X-100, 25 
&ml leupeptin and 25,ugIml aprotinin. The suspension was sonicated 
in glass tubes for I5 s, incubated on ice for 30 min and then spun in 
a microcentrifuge for IO min. The supernatant (detergent-solubilized 
membrane) was partially purified on DEAE cellulose columns. Both 
cytosol and membrane fractions were eluted with I .S ml of column 
buffer containing 200 mM NaCl as previously described [14]. The 
DEAE eluate was diluted in TEM containing 200 ,uM NaCl to obtain 
a range of three different enzyme concentrations. Protein kinasc C 
activity was determined as described [I 5. and Protein Kinase C Assay 
System, Gibco BRL, Grand Island, NY]. The partially purified pro- 
tein extract in TEM/NaCl was incubated for 5 min at 30°C in phos- 
pholipid (phosphatidyl serine and phorbol ester in Triton X- 100 mixed 
micelles: Gibco BRL), [y-‘*P]ATP and protein kinase C synthetic 
peptide [Se?“] PKC(l9- 31) (Gibco BRL). All assays were also per- 
formed in the presence of a protein kinase C inhibitor peptide (Gibco 
BRL) to ensure specificity of the phosphorylation reaction. The sam- 
ples were dried on phosphocellulose. washed in I% HIPO, and assayed 
by scintillation counting. Protein kinase C activity was determined as 
described in the Protein Kinase C Assay System (Gibco BRL). 
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Fig. 2. Activation and translocation of protein kinase C in TPA- 
treated HL-60 cells. HL-60 cells were treated with 32 nM TPA. At the 
indicated times, cells were harvested, lysed, and cytosol and mem- 
branc-bound fractions prepared. Protein kinasc C activity was assayed 
using a synthetic peptide substrate as described in section 2. Protein 
kinasc C (PKC) activity of the membrane (B) and cytosolic (0) frac- 
tions are expressed as nmollminimg protein. 
3. RESULTS 
Fig. 1 demonstrates the biphasic effect of TPA on 
c-nzyc mRNA levels. The c-nzyc gene is constitutively 
expressed in HL-60 cells and exposure to 32 nM TPA 
was associated with an increase in c-tnyc transcripts that 
was maximal at 60 min (Fig. 1). In contrast, longer TPA 
exposures resulted in a progressive decline in c-myc ex- 
pression to nearly undetectable levels by 6 h (Fig. I). 
These findings were compared to the effects of TPA on 
protein kinase C activation. Treatment of HL-60 cells 
with 32 nM TPA was associated with a translocation of 
protein kinase C activity from the cytosol to the mem- 
brane fraction (Fig. 2). This activation of protein kinase 
C was maximal at 30 min and corresponded to the 
maximal increases in c-myc expression. In contrast, ex- 
posure to TPA for l-3 h was associated with a partial 
down-regulation in membrane-associated protein ki- 
nase C activity (Fig. 2). These findings suggested that 
down-regulation, rather than activation, of protein ki- 
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Fig. 3. Effects of the protein kinase inhibitors H7 and HA1004 on 
c-my expression in HL-60 cells. HL-60 cells were treated with IOpM 
H7 (A) or IO ,uM HA1004 (B). Total cellular RNA (20,&lane) was 
isolated at the indicated times for hybridization with the labeled c-myc 
and actin probes. 
Fig. 4. Effbcts of the protein kinase inhibitors H7 and HA1004 on 
c-myc expression in u-937 cells. u-937 cells were treated with 10 PM 
H7 (A) or IO PM HA1004 (B). Total cellular RNA (20 ,ug/lane) was 
isolated at the indicated times for Northern analysis with the labeled 
c-my and actin probes. 
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nase C might contribute to decreases in c-myc expres- 
sion. 
In order to further address the effects of protein ki- 
nase C down-regulation on c-n?yc mRNA levels, we 
used H7. an isoquinolinsulfonamide inhibitor of this 
enzyme [161. Exposure of HL-60 cells to H7 resulted in 
a decrease in c-nr~~ transcripts to nearly undetectable 
levels by 60 min (Fig. 3A). In contrast, H7 had no 
detectable ffect on actin mRNA levels (Fig. 3A). Since 
H7 also inhibits cyclic nucleotide dependent protein ki- 
nascs, we performed similar experiments with HA1004, 
an agent related to H7 with more selective effects 
against CAMP and CAMP dependent protein kinases 
[17]. Exposure of HL-60 cells to HA1004 had no effect 
on either c-myc or actin expression (Fig. 3B). In order 
to determine whether these effects were restricted to 
HL-60 cells, we performed additional studies with the 
U-937 cell line. Exposure of U-937 cells to H7 similarly 
resulted in a rapid decrease in c-tnyc transcripts, while 
there was no change in actin expression (Fig. 4A). In 
contrast, exposure of U-Y37 cells to HA1004 had little 
effect on either c-nzyc or actin mRNA levels (Fig. 4B). 
Taken together, these findings indicated that the effects 
of H7 on c-myc expression were related to inhibition of 
protein kinase C and not cyclic nucleotide-dependent 
protein kinases. 
Other studies were performed with staurosporine, a 
structurally distinct inhibitor of protein kinase C [18]. 
Exposure of HL-60 cells to this agent resulted in down- 
regulation of c-myc expression to nearly undetectable 
levels by 1 h (Fig. 5A). c-myc mRNA levels were also 
decreased following staurosporine treatment of U-937 
cells (Fig. 5B). These changes in c-myc expression were 
associated with little if any effect on actin mRNA levels. 
Recent studies have demonstrated that sangivamycin, a
member of the pyrrolo[2,3-dlpyrimidine class of nucleo- 
side analogues, is a potent inhibitor of protein kinase C 
[19,20]. Exposure of U-937 cells to sangivamycin was 
also associated with a decrease in c-myc mRNA levels 
(Fig. 6). Taken together, these data suggest hat multi- 
ple agents which inhibit protein kinase C activity are 
associated with down-regulation of c-myc expression. 
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Fig. 5. Effects of the protein kinase inhibitor staurosporine (STSP) on 
c-r?ryc expression in HL-60 and U-937 cells. HL-60 cells (A) and U-937 
cells (B) were treated with 50 PM staurosporine. Total cellular RNA 
(20/@lane) was isolated at the indicated times for hybridization to the 
labeled c-nzyc and actin probes. 
4. DISCUSSION 
A decrease in c-myc gene expression is a necessary 
step for hematopoietic ell differentiation. For example, 
Friend murine erythroleukemia (MEL) cells transfected 
with constitutively expressed c-myc sequences are resi- 
stant to induction of differentiation 1211. In addition, 
c-myc antisense oligonucleotides inhibit HL-60 cell 
growth [9] and accelerate MEL cell differentiation in 
response to DMSO [22]. The precise mechanism where- 
by the c-myc protein regulates growth and differentia- 
tion is unclear, however there is recent data to suggest 
that c-myc may function in part as a transcriptional 
repressor, perhaps through its effect on other transcrip- 
tion factors such as CTF/NF-1 [23]. 
Although much is known about the regulation of 
c-tnyc gene expression, little is known about the second 
messenger pathways involved in controlling the de- 
crease in its expression during hematopoietic differen- 
tiation. Treatment of MEL cells with DMSO results in 
an early decrease in inositol-triphosphate and diacylgly- 
cerol levels which precedes the decrease in both c-myc 
gene and protein expression [24]. As diacylglycerol is 
the physiological activator of protein kinase C [25], 
these findings suggested a possible relationship between 
a decrease in kinase activity and a decrease in c-myc 
expression. Taken together with the results presented in 
this study, the decrease in c-myc expression seen during 
hematopoietic differentiation may be due in part to the 
down-regulation of protein kinase C. Further studies 
will be needed to define the role of the catalytically 
active fragment PKM [3], as well as that of the indivi- 
dual protein kinase C isoenzymes [26-281 in c-myc regu- 
lation. 
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Fig. 6. Effects of the protein kinase inhibitor sangivamycin on c-myc 
expression in U-937 cells. U-937 cells were treated with 1OpM sangi- 
vamycin. Total cellular RNA (20,@lane) was isolated at the indicated 
times for hybridization to the labeled c-myc and actin probes. 
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